ENHABIT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.27 USD | +3.58% |
|
+2.54% | -10.43% |
| May. 14 | Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target is $8.50 | MT |
| May. 10 | UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.89 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.75 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.43% | 449M | - | ||
| +1.21% | 3.14B | B- | ||
| 0.00% | 1.96B | - | ||
| +19.29% | 1.79B | C | ||
| +70.11% | 695M | D+ | ||
| -46.15% | 309M | - | ||
| -19.78% | 170M | - | ||
| -15.85% | 134M | - | ||
| +3.85% | 67.96M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EHAB Stock
- Ratings Enhabit, Inc.